Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Preclinical studies establish the conditions for safe and effective correction of SCID-X1 by targeted gene editing of hematopoietic stem cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [40]
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · cited 1×
“It exploits artificial nucleases, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and RNA-based CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) nucleases, to target a DNA double-strand break (DSB) or nick into a prede…”
BackgroundDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184 · cited 1×
“Whereas extensive clinical data show safe, robust, and stable engraftment of LV-modifiedHSCs in several disease settings (36), the specific features of SCID-X1 discussed above may exacerbate any residual risk of insertional mutagenesis and constitutive transgene expression, supporting the potential benefits of a more…”
BackgroundSelf-citationA guide to genome engineering with programmable nucleases
Kim, H., & Kim, J.-S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3686 · Cited by 1,163 · cited 1×
“It exploits artificial nucleases, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and RNA-based CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) nucleases, to target a DNA double-strand break (DSB) or nick into a prede…”
BackgroundSustained Correction of X-Linked Severe Combined Immunodeficiency by ex Vivo Gene Therapy
Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.-P., Thrasher, A. J., Wulffraat, N., Sorensen, R., Dupuis-Girod, S., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012616 · Cited by 1,058
Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain
Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsail, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90047-0 · Cited by 1,038
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Cited by
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Schiroli, G., Conti, A., Ferrari, S., della Volpe, L., Jacob, A., Albano, L., Beretta, S., Calabria, A., Vavassori, V., Gasparini, P., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.02.019 · Cited by 342
Self-citationThe delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Gene therapy using haematopoietic stem and progenitor cells
Ferrari, G., Thrasher, A. J., & Aiuti, A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00298-5 · Cited by 254
Mogensen, T. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03047 · Cited by 231
Metadata
- Authors
- Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., Bovolenta, C., Palchaudhuri, R., Scadden, D. T., Holmes, M. C., Villa, A., Sitia, G., Lombardo, A., Genovese, P., & Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Sangamo BioSciences (United States) (US)
- San Raffaele Telethon Institute for Gene Therapy, 20132 Milan, Italy.
- The San Raffaele Telethon Institute for Gene Therapy (IT)
- IRCCS Ospedale San Raffaele (IT)
- Newcastle University (GB)
- MolMed (Italy) (IT)
- Harvard University (US)
- Institute of Genetic and Biomedical Research (IT)
- San Raffaele Scientific Institute, 20132 Milan, Italy.
- Corresponding author
- Genovese, Pietro
- Naldini, Luigi
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-10-11
- Volume
- 9
- Issue
- 411
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2761956671
- Semantic Scholar
- 0b20261f7b2a459c0fcbfd7dd9fc81ab52120012
- Cited by
- 214
- References
- 44
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 20 · 2023: 28 · 2022: 25 · 2021: 37 · 2020: 30 · 2019: 33 · 2018: 18 · 2017: 3
- FWCI
- 15.27
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Seventh Framework Programme (award304283, FP7 601958 SUPERSIST)
- Fondazione Telethon (award304278, TIGET grant D2 2011-15, award304279, TIGET grant E1 2016, award304285, TIGET grant E3 2016)
- Ministero della Salute (award304284, NET-2011-02350069, award304286, GR-2013-02358956)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- X-linked severe combined immunodeficiency, hematopoietic stem cells, genome editing, zinc finger nucleases, CRISPR/Cas9, gene correction, long-term repopulating cells, preclinical modeling, clinical translation
- MeSH terms
- Gene Editing, Animals, Hematopoietic Stem Cells, Mice, SCID, Gene Targeting, Mice, Interleukin Receptor Common gamma Subunit, Clustered Regularly Interspaced Short Palindromic Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. https://app.cochat.ai/papers/10.1126/scitranslmed.aan0820
- The paper
- Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., Bovolenta, C., Palchaudhuri, R., Scadden, D. T., Holmes, M. C., Villa, A., Sitia, G., Lombardo, A., Genovese, P., & Naldini, L. (2017). Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aan0820
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.